loading...| Preferred Name |
deferasirox |
|
| Synonyms |
Exjade |
|
| Definitions |
A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availablity,and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48384" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48384" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000435986 |
|
| altLabel |
Exjade ICL670 |
|
| cui |
C1619629 C1609706 C0971122 |
|
| DATE FIRST PUBLISHED |
2005-06-08 |
|
| Date last modified |
2008-03-03 |
|
| definition |
A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availablity,and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48384" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48384" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C48384 |
|
| notation |
CDR0000435986 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
deferasirox |
|
| tui |
T109 T121 |